ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
19.984,32
0,74%
S&P 500
5.970,84
-1,11%
Dow Jones
42.992,21
-0,77%
Euro vs US Dollar
1,0428
0,02%
Bitcoin
95.106,91
1,00%
Pepperstone
Advertisement
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Connect Biopharma Holdings Inc (CNTB)

  7. Connect Biopharma Holdings Inc (CNTB) News

CNTB

Connect Biopharma (CNTB)

Connect Biopharma Holdings Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:CNTB
DatumZeitQuelleÜberschriftSymbolFirma
23/12/202422h05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CNTBConnect Biopharma Holdings Inc
15/10/202413h30GlobeNewswire Inc.Attovia Therapeutics Appoints Chief Financial OfficerNASDAQ:CNTBConnect Biopharma Holdings Inc
10/09/202414h00GlobeNewswire Inc.Connect Biopharma to Participate in the Cantor Fitzgerald Global Healthcare Conference 2024NASDAQ:CNTBConnect Biopharma Holdings Inc
06/09/202423h01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CNTBConnect Biopharma Holdings Inc
05/09/202422h05GlobeNewswire Inc.Connect Biopharma Reports First Half 2024 Financial Results and Provides Business UpdateNASDAQ:CNTBConnect Biopharma Holdings Inc
02/08/202423h13Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CNTBConnect Biopharma Holdings Inc
12/06/202422h47Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CNTBConnect Biopharma Holdings Inc
28/02/202403h00Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:CNTBConnect Biopharma Holdings Inc
13/02/202422h30Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:CNTBConnect Biopharma Holdings Inc
13/02/202422h27Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:CNTBConnect Biopharma Holdings Inc
13/02/202422h18Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:CNTBConnect Biopharma Holdings Inc
12/02/202422h50Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CNTBConnect Biopharma Holdings Inc
12/12/202312h10Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CNTBConnect Biopharma Holdings Inc
21/11/202312h13Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CNTBConnect Biopharma Holdings Inc
01/11/202320h57Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CNTBConnect Biopharma Holdings Inc
20/10/202322h44Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CNTBConnect Biopharma Holdings Inc
12/09/202322h47Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CNTBConnect Biopharma Holdings Inc
12/09/202312h13Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CNTBConnect Biopharma Holdings Inc
14/07/202323h00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CNTBConnect Biopharma Holdings Inc
23/06/202322h32Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:CNTBConnect Biopharma Holdings Inc
01/06/202322h25Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:CNTBConnect Biopharma Holdings Inc
11/04/202322h59Edgar (US Regulatory)Annual and Transition Report (foreign Private Issuer) (20-f)NASDAQ:CNTBConnect Biopharma Holdings Inc
11/04/202322h05GlobeNewswire Inc.Connect Biopharma Reports Full Year 2022 Financial Results and Provides Business UpdateNASDAQ:CNTBConnect Biopharma Holdings Inc
21/03/202321h53Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:CNTBConnect Biopharma Holdings Inc
18/03/202319h40Business WireConnect Biopharma CBP-201 Atopic Dermatitis China Pivotal Study Showed Rapid Relief of Patient SymptomsNASDAQ:CNTBConnect Biopharma Holdings Inc
17/03/202321h05Business WireConnect Biopharma CBP-201 Atopic Dermatitis Global Phase 2b Data Showed Rapid and Sustained Improvement Across all Body RegionsNASDAQ:CNTBConnect Biopharma Holdings Inc
06/03/202314h15Business WireConnect Biopharma CBP-201 Atopic Dermatitis Abstracts from Two Trials Accepted for Presentation at the American Academy of Dermatology (AAD) Annual MeetingNASDAQ:CNTBConnect Biopharma Holdings Inc
14/02/202312h33Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:CNTBConnect Biopharma Holdings Inc
09/02/202316h02Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:CNTBConnect Biopharma Holdings Inc
09/02/202312h07Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:CNTBConnect Biopharma Holdings Inc
 Showing the most relevant articles for your search:NASDAQ:CNTB

Kürzlich von Ihnen besucht

USOTC
SAPX
Seven Arts Entertainment (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten